Waters Corporation Launches Advanced BD BACTEC FXI System for Enhanced Blood Infection Diagnostics

On June 3, 2026, Waters Corporation celebrated a significant milestone with the FDA's clearance of the BD BACTEC FXI Culture System, marking a transformative advancement in the realm of bloodstream infection diagnostics. This state-of-the-art system aims to enhance diagnostic capabilities for laboratories across the United States by providing faster, more accurate, and fully automated blood culture results.

The BD BACTEC FXI Culture System stands out by reducing the average time to detect pathogens by nearly three hours—a roughly 15% decrease in comparison to its predecessor, the BD BACTEC FX Blood Culture System. This accelerated detection is crucial, particularly in acute care settings, where each hour of delayed sepsis treatment can significantly increase the risk of mortality, by as much as 9.9%. Hence, the system enables healthcare professionals to identify infections sooner and implement targeted antimicrobial therapies more quickly, ultimately improving patient outcomes.

One of the flagship innovations of the BD BACTEC FXI is its automating gravimetric measurement of blood culture vial volumes. This unique capability allows for the objective verification of blood volumes in each vial, thus minimizing pre-analytical variability, which is often a substantial source of diagnostic inconsistency.

Additionally, this new system boasts an industry-leading automated loading capacity, capable of managing 60 vials simultaneously—50% more than its closest competitor. This increased capacity ensures that high-volume microbiology laboratories can operate more efficiently, maximizing staff productivity while minimizing necessary manual interventions.

Waters Corporation has underscored the importance of this technology through comments from Jianqing Bennett, Senior Vice President of Waters Advanced Diagnostics. Bennett stated that this system not only reflects a considerable leap forward in diagnostic technology but also signifies a dedication to enhancing patient care and clinical outcomes, especially for patients facing the urgency of sepsis and bloodstream infections.

The BD BACTEC FXI Culture System is available in two configurations, accommodating 480 and 960 vials, making it a versatile choice for laboratories aiming to scale their operations and improve workflow efficiencies. Moreover, it has also received CE marking under the European Union's In Vitro Diagnostic Regulation and has been licensed by the Japan Pharmaceuticals and Medical Devices Agency for use in those regions.

In essence, the introduction of the BD BACTEC FXI Culture System represents a pivotal advancement in medical diagnostics, promising to aid laboratories in speeding up the detection process, improving accuracy in testing, and ultimately enhancing patient outcomes across the board. As Waters Corporation continues to lead innovations in life sciences and diagnostics, the medical community looks forward to seeing the positive impacts this system will have in practice.

For more information about the BD BACTEC FXI Culture System and other innovative products from Waters Corporation, please visit their official website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.